Topical erythromycin for acne vulgaris.
The clinical response of topical erythromycin (1%) in a new penetrative vehicle was evaluated in a double-blind investigation on 28 patients with severe and moderate acne vulgaris. The verum preparation was superior to the placebo in 21 of the patients, while in 4 the reverse was true and in 3 no differences were seen. It is thus obvious that topical erythromycin in the penetrative vehicle is a potent agent for acne treatment. The risk for development of resistant Propionibacterium acnes strains must, however, be considered in topical as well as in systemic antibiotic therapy of acne vulgaris.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004917:Erythromycin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009823:Ointment Bases
D009823:Ointment Bases; D004917:Erythromycin